+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.

Age: 18Years +All GendersPhase 3
143 locations
I

Actively Recruiting

Researchers are studying the effectiveness and safety of a combination drug called eloralintide and tirzepatide EloraTZP compared to tirzepatide alone for reducing body weight in adults who have obesity or are overweight and also have type 2 diabetes. This Phase 3 trial aims to understand how these treatments affect weight loss and other health measures over time. Participants will be randomly assigned to receive either EloraTZP or tirzepatide, both given by subcutaneous injection. The study involves a double-blind design, meaning neither participants nor researchers know which treatment is given. The treatment period lasts for about 100 weeks, during which participants receive regular doses and monitoring. During the study, participants will have their body weight and other health indicators, such as waist circumference, blood sugar levels, blood pressure, cholesterol, and quality of life, regularly measured from the start through week 100. Researchers will also monitor safety through laboratory tests and pharmacokinetic assessments. Overall participation in the study lasts about two years, with ongoing evaluations to understand the treatments effects and safety.

Age: 18Years +All GendersPhase 3
75 locations
E

Actively Recruiting

Researchers are evaluating the early use of empagliflozin, taken once daily by mouth, in patients hospitalized with acute heart failure who are at high risk of complications. This Phase 3, multicenter, randomized, double-blind trial compares empagliflozin to a placebo to assess its safety and effectiveness. The study is sponsored by Juntendo University and focuses on important outcomes like death, rehospitalization, worsening heart failure, and urine output within 90 days of treatment. Participants will be randomly assigned to receive either empagliflozin 10 mg once daily or a matching placebo. Treatment begins within 12 hours of hospital presentation. Both groups will be closely monitored during hospitalization and for up to 90 days after starting the study drug. The study uses a quadruple-blind design, meaning patients, caregivers, investigators, and assessors do not know which treatment is given. During the study, participants will undergo various assessments including monitoring of heart failure symptoms, urine output, blood tests for heart and kidney function, and quality of life questionnaires. Researchers will measure outcomes such as death rates, heart failure rehospitalizations, symptom changes, and kidney function over 90 days. Safety will be closely tracked throughout the study period. Total participation time varies but includes hospital stay and follow-up visits up to 90 days.

Age: 20Years +All GendersPhase 3
69 locations